Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tranexamic acid - Hyloris Pharmaceuticals

Next Previous
Drug Profile

Tranexamic acid - Hyloris Pharmaceuticals

Alternative Names: HY-REF-004; HY004 - Hyloris Pharmacecuticals; Tranexamic acid RTU - Hyloris Pharmaceutical; TXA acid RTU; TXA acid RTU - Hyloris Pharmaceuticals

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hyloris Pharmaceuticals
  • Developer Hyloris Pharmaceuticals; Undisclosed Company
  • Class Amines; Anti-infectives; Anti-inflammatories; Antifibrinolytics; Antihaemorrhagics; Cardiovascular therapies; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Haemophilia; Haemorrhage
  • No development reported Unspecified

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Unspecified in Belgium (PO)
  • 14 Feb 2024 Phase-III clinical trials in Haemorrhage (Prevention) in USA, Europe (PO)
  • 14 Feb 2024 Hyloris Pharmaceuticals plans to seek regulatory approval for tranexamic acid in Hemorrhage in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top